We are live on ! Find out more
FCMV

Foresite Capital Management VI Portfolio holdings

AUM $460M
1-Year Est. Return 261.77%
This Fund
S&P 500
This Quarter Est. Return
-0.81%
1 Year Est. Return
+261.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$178M
AUM Growth
-$4.66M
Cap. Flow
+$12.3M
Cap. Flow %
6.9%
Top 10 Hldgs %
83.94%
Holding
20
New
6
Increased
2
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$8M
2
HNGE
Hinge Health
HNGE
+$5.46M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$5.22M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$2.77M
5
RNAM
Avidity Biosciences
RNAM
+$1.19M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$5.46M
2
GPCR icon
Structure Therapeutics
GPCR
+$4.62M
3
CASI
CASI Pharmaceuticals
CASI
+$994K
4
ALLO icon
Allogene Therapeutics
ALLO
+$761K
5
CGEM icon
Cullinan Oncology
CGEM
+$326K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.33B
$57.8M 32.47%
2,221,474
– –
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$16.5M 9.26%
1,253,379
– –
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$13.1M 7.35%
244,900
-120,100
-33% -$5.46M
ALMS
4
Alumis Inc
ALMS
$3.45B
$12.7M 7.16%
4,247,670
+45,000
+1% +$213K
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$12.5M 7.03%
1,562,500
– –
BCAX
6
Bicara Therapeutics
BCAX
$1.75B
$8.82M 4.96%
949,260
-740
-0.1% -$8.82K
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.37B
$7.67M 4.31%
585,000
– –
HNGE
8
Hinge Health
HNGE
$5.82B
$6.99M 3.93%
+135,000
New +$5.46M
CRVS icon
9
Corvus Pharmaceuticals
CRVS
$1.11B
$6.92M 3.89%
1,731,233
+150,000
+9% +$546K
KYMR icon
10
Kymera Therapeutics
KYMR
$8.77B
$6.39M 3.59%
146,332
– –
VSTM icon
11
Verastem
VSTM
$539M
$5.3M 2.98%
+1,276,520
New +$8M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.28B
$5.01M 2.82%
+160,000
New +$5.22M
CGEM icon
13
Cullinan Oncology
CGEM
$1.07B
$4.47M 2.51%
594,025
-40,533
-6% -$326K
GPCR icon
14
Structure Therapeutics
GPCR
$3.41B
$4.36M 2.45%
210,000
-210,000
-50% -$4.62M
ALLO icon
15
Allogene Therapeutics
ALLO
$566M
$3.25M 1.83%
2,875,357
-572,918
-17% -$761K
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.46B
$3.04M 1.71%
+144,468
New +$2.77M
RNAM
17
DELISTED
Avidity Biosciences
RNAM
$1.14M 0.64%
+40,000
New +$1.19M
SYRE icon
18
Spyre Therapeutics
SYRE
$8.67B
$1.05M 0.59%
+70,000
New +$1.04M
CASI
19
DELISTED
CASI Pharmaceuticals
CASI
$929K 0.52%
787,121
-542,262
-41% -$994K
VRDN icon
20
Viridian Therapeutics
VRDN
$2.15B
$27.6K 0.02%
1,974
– –

Similar funds

MCB
Morton Community Bank East Peoria, Illinois $460M AUM 17.72% 1-Year Est. Return
WCM
Weaver Capital Management Suwanee, Georgia $461M AUM 20.77% 1-Year Est. Return
PC
Pureheart Capital Singapore $459M AUM 23.59% 1-Year Est. Return
PIN
Prudent Investors Network Lake Forest, California $459M AUM 9.48% 1-Year Est. Return
FCG
Fielder Capital Group Nashville, Tennessee $459M AUM 48.94% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

Foresite Capital Management VI's Q2 2025 Portfolio in Review

As of Q2 2025, Foresite Capital Management VI held 20 positions worth $178M, down 2.6% from $183M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Foresite Capital Management VI deployed $12.3M of net new capital in Q2 2025, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Verastem: 1,276,520 shares worth $5.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $5.46M trimmed.

  • Foresite Capital Management VI's largest Q2 2025 buy was Verastem: 1,276,520 shares worth $5.3M.
  • Foresite Capital Management VI added most to Corvus Pharmaceuticals in Q2 2025, an estimated $546K increase.
  • Foresite Capital Management VI's biggest Q2 2025 reduction was Akero Therapeutics, cutting an estimated $5.46M.
  • Foresite Capital Management VI's ten largest holdings make up 84% of its $178M portfolio in Q2 2025.
  • Foresite Capital Management VI opened 6 new positions and closed 0 in Q2 2025.
  • Foresite Capital Management VI's portfolio value fell 2.6% quarter-over-quarter to $178M.

Based on Foresite Capital Management VI's 13F filing for Q2 2025, filed 12 Aug 2025.